Professional Documents
Culture Documents
Onychomycosis - Epidemiology, Clinical Features, and Diagnosis - UpToDate
Onychomycosis - Epidemiology, Clinical Features, and Diagnosis - UpToDate
All topics are updated as new evidence becomes available and our peer review process is complete.
INTRODUCTION
Onychomycosis most often occurs in adults but also occurs in children. Common clinical
manifestations include nail discoloration, subungual hyperkeratosis, onycholysis, splitting of
the nail plate, and nail plate destruction ( picture 1A-B). Potential complications include
pain, transmission of fungal infection to other body sites, and, in immunocompromised
patients, bacterial cellulitis.
The epidemiology, clinical features, and diagnosis of onychomycosis will be reviewed here
( algorithm 1). Other causes of nail dystrophy and the management of onychomycosis are
reviewed separately. (See "Overview of nail disorders" and "Onychomycosis: Management".)
MICROBIOLOGY
Candida species are the most common yeasts isolated from onychomycosis [3,4]. Examples of
nondermatophyte molds found in onychomycosis include Fusarium, Aspergillus, Acremonium,
Scytalidium, and Scopulariopsis brevicaulis [5].
PATHOGENESIS
Onychomycosis is acquired through direct contact of the nail with dermatophytes, yeast, or
nondermatophyte molds in the environment or through spread of fungal infection from
affected skin (eg, tinea pedis). Fungal production of proteases that degrade keratin may
facilitate invasion [9]. Factors that can compromise barriers to infection, such as nail injury or
nail disease, may increase risk for fungal invasion. In addition, the status of the nail as a site
of relative immune privilege lacking effective cell-mediated immunity may contribute to
infection [10,11].
EPIDEMIOLOGY
Onychomycosis is more common in adults than in children. The systematic review cited above
found pooled prevalences of pediatric dermatophyte and yeast toenail onychomycosis of 0.14
percent (95% CI 0.11-0.18) and 0.09 percent (95% CI 0.06-0.13), respectively [14]. In a separate
systematic review that included pediatric studies assessing both toenail and fingernail
onychomycosis, prevalences of onychomycosis in children ranged from 0 to 3.37 percent in
population-based studies utilizing a combination of clinical diagnosis, microscopy, and
culture for diagnosis [15]. All but one of the studies reported prevalences of less than 1
percent.
Most, but not all, studies have found a higher prevalence of onychomycosis in males than in
females [2].
RISK FACTORS
Data on risk factors for onychomycosis are limited. Proposed risk factors include [1]:
● Exposures – Trauma, poor nail grooming, sports and fitness activities, occupation,
smoking, occlusive shoes
Candida albicans onychomycosis often occurs in association with frequent exposure of the
hands to moisture, as may occur in certain occupations (eg, bartenders, housekeepers) [7].
Rarely, severe candidal onychomycosis is a manifestation of chronic mucocutaneous
candidiasis, a heterogeneous group of syndromes characterized by deficient immune
responses against C. albicans and chronic candidal infections of the skin, mucous
membranes, and nails [16]. (See "Chronic mucocutaneous candidiasis".)
CLINICAL FEATURES
The infection gradually spreads to involve the entire width of the nail plate and extends
slowly toward the cuticle ( picture 1A-B). Subungual hyperkeratosis and onycholysis
(separation of the nail plate from the nail bed) are common. The accumulation of
keratinous debris between the nail plate and nail bed causes the nail discoloration.
The vast majority of distal lateral subungual onychomycosis is due to T. rubrum [8].
Chronic paronychia (inflammation of the proximal or lateral nail folds) is common in patients
with Candida onychomycosis. (See "Paronychia", section on 'Chronic paronychia'.)
COMPLICATIONS
Onychomycosis may also serve as a reservoir for recurrence of cutaneous fungal infections
(eg, tinea pedis, tinea cruris, tinea corporis). Additionally, in patients with diabetes or other
immunocompromised states, onychomycosis may increase the risk of bacterial infections,
such as cellulitis [26,27]. (See "Dermatophyte (tinea) infections".)
DIAGNOSIS
A diagnosis of onychomycosis may be strongly suspected based upon the patient history and
physical findings. However, confirmation of the diagnosis requires the detection of fungi in a
nail specimen through microscopic examination, culture, or other laboratory testing
( algorithm 1). (See "Onychomycosis: Management", section on 'Pretreatment diagnostic
testing'.)
Tests typically used to confirm onychomycosis in the clinical setting include potassium
hydroxide (KOH) preparations, fungal cultures, histopathologic examination with a periodic
acid-Schiff (PAS) stain, and polymerase chain reaction (PCR) [28]. In addition, fungal cultures
and PCR can identify the type of fungus present, and fungal culture can confirm fungal
viability, supporting the presence of active infection.
Our approach — A KOH preparation is our preferred initial test for suspected onychomycosis
given the rapid availability of results, relatively low cost, and simplicity of the procedure
( algorithm 1). However, the sensitivity of KOH preparation is lower than histopathologic
examination with a PAS stain or PCR, and the results are dependent upon skill of the
https://www.uptodate.com/contents/onychomycosis-epidemiology-clinical-features-and-diagnosis/print?search=tiña de la cabeza&topicRef=4030… 6/49
7/7/23, 21:20 Onychomycosis: Epidemiology, clinical features, and diagnosis - UpToDate
performing clinician. If the KOH preparation is negative, we typically obtain a nail clipping for
histopathologic examination with a PAS stain. A PCR test that assesses for dermatophytes,
saprophytes, and Candida is a less widely available alternative to histopathologic
examination.
If the KOH preparation or PAS stain is positive, confirming onychomycosis, we typically obtain
a nail sample for fungal culture to identify the causative organism (dermatophyte versus
yeast versus nondermatophyte mold) if the patient plans to proceed with treatment. PCR can
also provide identification of the organism.
PCR testing is also utilized by some clinicians as the initial diagnostic test for onychomycosis,
rather than a KOH preparation. Familiarity with the limitations of the specific PCR test
selected is crucial. (See 'Polymerase chain reaction' below.)
History and physical examination — Information from the patient history and physical
examination can help to narrow the differential diagnosis. Patients should be asked about the
duration and course of nail changes, preceding nail trauma, and history of skin disorders. In
patients with nail dystrophy involving all nails, additional historical details, such as inquiries
about systemic disease or family history of nail disorders, may be helpful for identifying
patients at risk for systemic or genetic causes of onychodystrophy. (See "Overview of nail
disorders", section on 'History' and "Overview of nail disorders", section on 'Nail signs of
systemic diseases'.)
The physical examination should include examination of all nails on the hands and feet to
determine the nature and extent of involvement. Examination of the skin is also useful for
identifying risk factors for onychomycosis, such as cutaneous fungal infections or chronic
paronychia, as well as cutaneous diseases that may cause noninfectious nail dystrophy, such
as psoriasis and lichen planus. Of note, onychomycosis is common and may coexist with
other nail disorders. (See "Overview of nail disorders", section on 'Nail examination' and
"Overview of nail disorders", section on 'Skin diseases with nail involvement'.)
Examples of features consistent with, but not exclusive to, onychomycosis include:
● Nail changes consistent with onychomycosis (eg, white, yellow, or brown discoloration,
subungual hyperkeratosis, onycholysis, splitting, nail destruction) (see 'Subtypes' above)
Dermoscopy of the nails may help to distinguish onychomycosis from other nail disorders. A
jagged proximal edge near areas of onycholysis, also described as an irregular macular
pattern, is a common finding that is postulated to occur in the setting of distal to proximal
https://www.uptodate.com/contents/onychomycosis-epidemiology-clinical-features-and-diagnosis/print?search=tiña de la cabeza&topicRef=4030… 7/49
7/7/23, 21:20 Onychomycosis: Epidemiology, clinical features, and diagnosis - UpToDate
Diagnostic tests — The major diagnostic tests for onychomycosis include KOH preparations,
histopathologic examination of nail clippings with a PAS stain, fungal culture, and PCR.
The technique for obtaining the specimen is critical to the success of this procedure. In the
evaluation of distal lateral subungual onychomycosis, the nail should be clipped back as far
as possible and samples taken from the most proximal accessible region. Subungual debris
overlying the nail bed can be obtained with a curette. Specimens from proximal subungual
onychomycosis can be obtained by paring the overlying nail plate to allow sampling of the
ventral nail plate. In white superficial onychomycosis, the sample can be taken by scraping
the surface of involved areas with a number 15 blade.
A positive test demonstrates fungal hyphae, pseudohyphae, or yeast cells ( picture 10). The
KOH examination does not provide speciation or assess fungus viability.
PAS staining of nail clippings is a sensitive test for onychomycosis [34-37]. One study included
1146 nail samples from 851 patients with clinical findings suggestive of onychomycosis [36].
Results from this study indicate that the PAS stain is a more sensitive test than culture or KOH
examination; sensitivities of PAS stain, culture, and KOH examination were 82, 53, and 48
percent, respectively.
To obtain a specimen for a PAS stain from distal lateral subungual onychomycosis, the nail
plate along with attached subungual debris is clipped just distal to its attachment to the nail
bed and placed in 10% formalin [35]. Nail clipping can also provide a sufficient specimen for
white superficial onychomycosis with distal nail involvement. Histopathologic examination of
https://www.uptodate.com/contents/onychomycosis-epidemiology-clinical-features-and-diagnosis/print?search=tiña de la cabeza&topicRef=4030… 8/49
7/7/23, 21:20 Onychomycosis: Epidemiology, clinical features, and diagnosis - UpToDate
proximal subungual onychomycosis is more challenging; a biopsy of the nail plate or partial
or full nail removal is usually necessary, making this diagnostic technique less favorable.
In a positive PAS stain, fungal elements (eg, hyphae, yeast) are typically found in the ventral
layers of the nail plate and in subungual debris ( picture 11). If white superficial
onychomycosis is sampled, fungal elements are usually found in the dorsal surface of the nail
plate [37]. As with the KOH examination, a PAS stain does not provide speciation or assess
fungus viability.
The Chicago sky blue stain, which provides a color contrast, has also been used for the
diagnosis of onychomycosis [38].
Fungal culture — A fungal culture (on Sabouraud's medium) allows for both identification
and speciation of fungal infection and is a highly specific test (83 to 100 percent specificity)
[1,32]. However, the sensitivity of culture is not high (31 to 59 percent), and results often are
not available for a few weeks [1,32,39]. If negative, repeat culture or other testing is indicated
when there is a strong clinical suspicion of onychomycosis, since almost one-third of cultures
may be falsely negative.
Familiarity with the sensitivity, specificity, and other limitations of the specific PCR test(s)
available to the clinician is essential for proper use and interpretation of results. Some tests
are only able to assess for dermatophyte infections, whereas others assess broader
categories of fungi. In addition, because PCR tests detect DNA, nonviable fungi may be
detected. Sample collection and submission should be performed according to the product
recommendations.
Other tests — Less commonly employed alternative tests include the dermatophyte test
medium (DTM) and the calcofluor white stain:
Dermatophyte growth is indicated by a change in the color of DTM from yellow to red in
response to alkaline metabolites that result from growth of dermatophytes. It is
important to read DTM cultures in a timely fashion, since saprophytic organisms, which
might grow over several weeks, can cause the same color change. DTM cannot identify
the specific causative organism, but such identification is not necessary since all
dermatophytes are susceptible to similar therapies. In a study of 670 patients
presenting to their primary care clinician or podiatrist with clinical signs of toenail
onychomycosis, DTM cultures had good positive and negative correlation with culture
on Sabouraud's medium [43].
DIFFERENTIAL DIAGNOSIS
Nail psoriasis, traumatic nail injury, and onychogryphosis are common conditions that may
resemble onychomycosis. Testing to detect fungi in the nail distinguishes onychomycosis
from these and other conditions (see 'Diagnosis' above):
● Trauma – Traumatic nail injury can result in a wide variety of nail changes. A history of
trauma and exclusion of other disorders is essential for the diagnosis of trauma-induced
nail dystrophy. (See "Overview of nail disorders".)
In addition, nail changes associated with less frequent causes of nail dystrophy, such as
lichen planus ( picture 14A-B), eczema, pachyonychia congenita ( picture 15A-B), yellow
nail syndrome ( picture 16), median nail dystrophy ( picture 17), onychomatricoma
( picture 18), subungual exostosis ( picture 19), malignancy ( picture 20A-D), scabies
( picture 21) [50], and other disorders, may enter the differential diagnosis. The differential
diagnosis of nail disorders is reviewed in detail separately. (See "Overview of nail disorders".)
In patients with findings suggestive of fungal melanonychia, the possibility of other causes of
nail pigmentation, such as racial longitudinal melanonychia, exogenous pigment deposition,
and, most importantly, subungual melanoma, should be considered during patient
evaluation [20]. (See "Overview of nail disorders", section on 'Longitudinal melanonychia'.)
Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Dermatophyte
infections".)
UpToDate offers two types of patient education materials, "The Basics" and "Beyond the
Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th
grade reading level, and they answer the four or five key questions a patient might have
about a given condition. These articles are best for patients who want a general overview and
who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are
longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th
grade reading level and are best for patients who want in-depth information and are
comfortable with some medical jargon.
https://www.uptodate.com/contents/onychomycosis-epidemiology-clinical-features-and-diagnosis/print?search=tiña de la cabeza&topicRef=403… 11/49
7/7/23, 21:20 Onychomycosis: Epidemiology, clinical features, and diagnosis - UpToDate
Here are the patient education articles that are relevant to this topic. We encourage you to
print or e-mail these topics to your patients. (You can also locate patient education articles on
a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
● Basics topic (see "Patient education: Fungal nail infections (The Basics)")
● Complications – Onychomycosis may cause physical discomfort and may increase risk
for bacterial infections such as cellulitis in immunocompromised patients.
Onychomycosis can also serve as a reservoir for cutaneous fungal infections. (See
'Complications' above.)
A KOH preparation is commonly performed as the initial test based upon rapidity, wide
availability, and low cost; however, other approaches, such as use of PCR as the initial
test, may be reasonable ( algorithm 1). (See 'Diagnosis' above.)
REFERENCES
1. Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. J Am Acad
Dermatol 2019; 80:835.
2. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a
literature study. J Eur Acad Dermatol Venereol 2014; 28:1480.
3. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal
isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal
susceptibility patterns. J Am Acad Dermatol 2000; 43:641.
4. Gupta AK, Gupta G, Jain HC, et al. The prevalence of unsuspected onychomycosis and its
causative organisms in a multicentre Canadian sample of 30 000 patients visiting
physicians' offices. J Eur Acad Dermatol Venereol 2016; 30:1567.
5. Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical classification. J Am
Acad Dermatol 2011; 65:1219.
6. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in
patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. J
Am Acad Dermatol 2000; 43:244.
7. Romano C, Gianni C, Difonzo EM. Retrospective study of onychomycosis in Italy: 1985-
2000. Mycoses 2005; 48:42.
8. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal
infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004; 50:748.
9. Monod M, Méhul B. Recent Findings in Onychomycosis and Their Application for
Appropriate Treatment. J Fungi (Basel) 2019; 5.
10. Ito T, Ito N, Saathoff M, et al. Immunology of the human nail apparatus: the nail matrix is
a site of relative immune privilege. J Invest Dermatol 2005; 125:1139.
11. Grover C, Khurana A. Onychomycosis: newer insights in pathogenesis and diagnosis.
Indian J Dermatol Venereol Leprol 2012; 78:263.
12. Gupta AK, Daigle D, Carviel JL. The role of biofilms in onychomycosis. J Am Acad Dermatol
2016; 74:1241.
13. Gupta AK, Foley KA. Evidence for biofilms in onychomycosis. G Ital Dermatol Venereol
2019; 154:50.
14. Gupta AK, Daigle D, Foley KA. The prevalence of culture-confirmed toenail
onychomycosis in at-risk patient populations. J Eur Acad Dermatol Venereol 2015;
29:1039.
15. Vestergaard-Jensen S, Mansouri A, Jensen LH, et al. Systematic review of the prevalence
of onychomycosis in children. Pediatr Dermatol 2022; 39:855.
16. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis
exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest
Dermatol 2008; 128:2640.
19. Sigurgeirsson B. Prognostic factors for cure following treatment of onychomycosis. J Eur
Acad Dermatol Venereol 2010; 24:679.
20. Finch J, Arenas R, Baran R. Fungal melanonychia. J Am Acad Dermatol 2012; 66:830.
21. Szepietowski JC, Reich A, Garlowska E, et al. Factors influencing coexistence of toenail
onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients.
Arch Dermatol 2006; 142:1279.
22. Gupta AK, Mays RR. The Impact of Onychomycosis on Quality of Life: A Systematic
Review of the Available Literature. Skin Appendage Disord 2018; 4:208.
23. Lubeck DP, Gause D, Schein JR, et al. A health-related quality of life measure for use in
patients with onychomycosis: a validation study. Qual Life Res 1999; 8:121.
24. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol
1997; 36:754.
25. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life:
development of an international onychomycosis-specific questionnaire to measure
patient quality of life. J Am Acad Dermatol 1999; 41:189.
26. Roujeau JC, Sigurgeirsson B, Korting HC, et al. Chronic dermatomycoses of the foot as
risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology
2004; 209:301.
27. Bristow IR, Spruce MC. Fungal foot infection, cellulitis and diabetes: a review. Diabet Med
2009; 26:548.
28. Saunte DML, Piraccini BM, Sergeev AY, et al. A survey among dermatologists: diagnostics
of superficial fungal infections - what is used and what is needed to initiate therapy and
assess efficacy? J Eur Acad Dermatol Venereol 2019; 33:421.
29. Piraccini BM, Balestri R, Starace M, Rech G. Nail digital dermoscopy (onychoscopy) in the
diagnosis of onychomycosis. J Eur Acad Dermatol Venereol 2013; 27:509.
30. Yorulmaz A, Yalcin B. Dermoscopy as a first step in the diagnosis of onychomycosis.
Postepy Dermatol Alergol 2018; 35:251.
33. Meireles TE, Rocha MF, Brilhante RS, et al. Successive mycological nail tests for
onychomycosis: a strategy to improve diagnosis efficiency. Braz J Infect Dis 2008; 12:333.
34. Lilly KK, Koshnick RL, Grill JP, et al. Cost-effectiveness of diagnostic tests for toenail
onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7
diagnostic tests. J Am Acad Dermatol 2006; 55:620.
35. Lawry MA, Haneke E, Strobeck K, et al. Methods for diagnosing onychomycosis: a
comparative study and review of the literature. Arch Dermatol 2000; 136:1112.
36. Wilsmann-Theis D, Sareika F, Bieber T, et al. New reasons for histopathological nail-
clipping examination in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol
2011; 25:235.
37. Jung MY, Shim JH, Lee JH, et al. Comparison of diagnostic methods for onychomycosis,
and proposal of a diagnostic algorithm. Clin Exp Dermatol 2015; 40:479.
38. Lim CS, Lim SL. New contrast stain for the rapid diagnosis of onychomycosis. Arch
Dermatol 2011; 147:981.
39. Bosshard PP. Incubation of fungal cultures: how long is long enough? Mycoses 2011;
54:e539.
40. Shemer A, Davidovici B, Grunwald MH, et al. New criteria for the laboratory diagnosis of
nondermatophyte moulds in onychomycosis. Br J Dermatol 2009; 160:37.
41. Gupta AK. Treatment of dermatophyte toenail onychomycosis in the United States. A
pharmacoeconomic analysis. J Am Podiatr Med Assoc 2002; 92:272.
42. Gupta AK, Taborda VBA, Taborda PRO, et al. High prevalence of mixed infections in global
onychomycosis. PLoS One 2020; 15:e0239648.
43. Elewski BE, Leyden J, Rinaldi MG, Atillasoy E. Office practice-based confirmation of
onychomycosis: a US nationwide prospective survey. Arch Intern Med 2002; 162:2133.
44. Gupta AK, Zaman M, Singh J. Diagnosis of Trichophyton rubrum from onychomycotic nail
samples using polymerase chain reaction and calcofluor white microscopy. J Am Podiatr
Med Assoc 2008; 98:224.
45. Weinberg JM, Koestenblatt EK, Tutrone WD, et al. Comparison of diagnostic methods in
the evaluation of onychomycosis. J Am Acad Dermatol 2003; 49:193.
46. Tsunemi Y, Takehara K, Miura Y, et al. Screening for tinea unguium by Dermatophyte Test
Strip. Br J Dermatol 2014; 170:328.
49. Nath AK, Udayashankar C. Congenital onychogryphosis: Leaning Tower nail. Dermatol
Online J 2011; 17:9.
50. Zou Y, Hu W, Zheng J, Pan M. Nail infestation: an atypical presentation of typical scabies.
Lancet 2018; 391:2272.
Topic 4034 Version 34.0
GRAPHICS
Onychomycosis
Proximal, white discoloration of the nail plate is noted. The nail fold
is uninvolved.
Onychomycosis
Distal, lateral, subungual onychomycosis with associated toenail discoloration, subungual debris, and
dermatophytoma. Dermatophytomas appear as opaque, white or yellow, linear bands in the nail.
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Erythema and white, macerated skin between the toes in a patient with
tinea pedis.
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Multiple septate hyphae on a background of squamous cells in a KOH preparation taken from the site of a
dermatophyte infection.
Onychomycosis
Nail clippings stained with a periodic acid-Schiff (PAS) stain showing septal hyphal elements culture prove
Trichophyton species within the nail plate keratin.
Reproduced with permission from: Rubin AI, Griffin TD. Inflammatory diseases of the nail. In: Lever's Histopathology of the Skin, 1
Elder DE, Elenitsas R, Rosenbach M, et al (Eds), Wolters Kluwer, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. www.lww.com
Nail psoriasis
Crumbling of the nail plate resulting in loss of part of the dystrophic nail in a patient with nail psoriasis.
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Onychogryphosis
Onychogryphosis, also called "ram's horn nail," usually affects the great toenail
of older adult and neglected individuals. The nail appears thickened, yellow-brown in
color, increased in length, and distorted.
Image created by Ken Gross, MD. Reproduced with permission from: www.visualdx.com. Copyright VisualDx.
All rights reserved.
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Roughness, longitudinal ridging, and pitting of the nail plates on the fingers.
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Pachyonychia congenita
Pachyonychia congenita
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Onychomatricoma
Subungual exostosis
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Crusted scabies
Reproduced with permission from: www.visualdx.com. Copyright VisualDx. All rights reserved.
Contributor Disclosures
Adam O Goldstein, MD, MPH No relevant financial relationship(s) with ineligible companies to
disclose. Neal Bhatia, MD Grant/Research/Clinical Trial Support: Valeant Pharmaceuticals
[Onychomycosis, tinea pedis]. Consultant/Advisory Boards: Valeant Pharmaceuticals [Onychomycosis,
tinea pedis]. Speaker's Bureau: Valeant Pharmaceuticals [Onychomycosis, tinea pedis]. All of the
relevant financial relationships listed have been mitigated. Robert P Dellavalle, MD, PhD, MSPH Equity
Ownership/Stock Options: Altus Labs [Itch, eczema]. Grant/Research/Clinical Trial Support: Pfizer
[Patient decision aids, inflammatory and immune-mediated skin disease]. Other Financial Interest:
Cochrane Council meetings [Expense reimbursement]. All of the relevant financial relationships listed
have been mitigated. Moise L Levy, MD Grant/Research/Clinical Trial Support: Castle Creek Biosciences
[Epidermolysis bullosa]; Janssen Pharmaceuticals [Psoriasis]; Krystal Biotech [Epidermolysis bullosa];
Regeneron Pharmaceuticals [Atopic dermatitis]. Consultant/Advisory Boards: Abeona Therapeutics
[Epidermolysis bullosa]; Castle Creek Biosciences [Epidermolysis bullosa]; Novan [Molluscum
contagiosum treatment]; Regeneron Pharmaceuticals [Atopic dermatitis]. Other Financial Interest:
Mayne Pharma [Data and safety monitoring board for ichthyosis trial]. All of the relevant financial
relationships listed have been mitigated. Ted Rosen, MD Consultant/Advisory Boards: Almirall [Actinic
keratosis]; Beiersdorf [Dry skin]; DermTech [Melanoma]. All of the relevant financial relationships listed
have been mitigated. Abena O Ofori, MD No relevant financial relationship(s) with ineligible companies
to disclose.
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these
are addressed by vetting through a multi-level review process, and through requirements for references
to be provided to support the content. Appropriately referenced content is required of all authors and
must conform to UpToDate standards of evidence.